Trillium Health Resources Pharmacy Prior Approval Request for



PCSK9 Inhibitors: Praluent and Repatha

Me	Member Information				
1.	. Last Name: 2. First Name: 5. Gender: 5. Gender: 5.				
3.	3. Trillium ID #:	4. Date of Birth:	5. Gende	er:	
	Prescriber Information				
1.	Prescriber Name: 2. NPI #:				
3.	3. Requestor Name (Nurse/Office Staff):				
4.	4. Mailing Address:3. Phone #:	City:	State:	Zip:	
3.	3. Phone #:	Ext Fax	<pre><#:</pre>		
Dru	Orug Information				
1.	1. Drug Name:	2. Strength:	3. Quantity Per 30 Day	/s:	
	4. Length of Therapy (in Days): \qed up to 30 Days \qed				
Clin	Clinical Information				
1. 2. 3. 4. 5. 6. ***[7.	rosuvastatin (generic for Crestor) AND has constant to the member's LDL level > 70 mg/dl after take Crestor) for 90 days? ☐ Yes ☐ No 3. Does the member have a significant intolerant rosuvastatin (generic for Crestor)? Examples abnormalities, and rhabdomyolysis. Intolerant ☐ Yes ☐ No 4. Has documentation of clinically significant into prior approval request? ☐ Yes ☐ No 5. Baseline LDL before statin treatment:	ompleted 90 days of treating atorvastatin (generic ace or allergic reaction to of significant intolerance ace does not include fatiguallerance or allergic reaction to the stream of the	ment? Yes No for Lipitor) or rosuvastatin (ger atorvastatin (generic for Lipitor include severe muscle pain, si ue, cognitive impairment, or mil on to statin treatment been atta	neric for or ignificant liver ld aches. ached to this	
CI	Clinical Questions for Praluent (8-12, 18, 19):				
8.	8. Is the member 18 years of age or older? \square Ye	es □ No			
9.	Does the member have a diagnosis of Heterozygous Familial Hypercholesterolemia? \square Yes \square No				
11	 10. Does the member have a diagnosis of Homozen 11. Does the member have clinical atherosclerotic history of myocardial infarction, stable or unstatransient ischemic attack, or peripheral arteria 12. Does the member have a diagnosis of Severe □ Yes □ No 	c cardiovascular disease table angina, coronary or al disease of atherosclero	such as acute coronary syndro other arterial revascularization otic origin? Yes No	ı, stroke,	
CI	Clinical Questions for Repatha (13-17, 18, 19):				
			olesterolemia (HeFH)? □ Yes	□No	
		Does the member have a diagnosis of Heterozygous Familial Hypercholesterolemia (HeFH)? Yes No No			
	15. Is the member 10 years or older? ☐ Yes ☐ N				
	Does the member have clinical atherosclerotic cardiovascular disease such as acute coronary syndromes, or a history of myocardial infarction, stable or unstable angina, coronary or other arterial revascularization, stroke, transient ischemic attack, or peripheral arterial disease of atherosclerotic origin? Yes No				

Trillium Health Resources Pharmacy Prior Approval Request for



Transforming Lives, Building Community Well-Being,

17. Does the member have a diagnosis of Severe Primary I☐ Yes ☐ No	-lyperlipidemia (defined as LDL -C > 190mg/dL)?				
Continuation Questions for Praluent and Repatha: 18. Has the provider submitted documentation that indicates ☐ Yes ☐ No	s a positive clinical response to therapy with this request?				
19. Is the member continuing to receive other lipid-lowering therapy? ☐ Yes ☐ No					
20. Is the member currently receiving more than one PCSK9 inhibitor? ☐ Yes ☐ No					
Signature of Prescriber:	_ Date:				
(Prescriber Signature Ma	andatory)				
I certify that the information provided is accurate and co that any falsification, omission, or concealment of mater	,				